BRACAnalysis CDx
FDA premarket approval P140020/S018 · decided 2018-12-19
Approval details
- PMA number
- P140020
- Supplement
- S018
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- BRACAnalysis CDx
- Generic name
- Cancer-related germline gene mutation detection system
- Applicant
- Myriad Genetic Laboratories
- Date received
- 2018-09-21
- Decision date
- 2018-12-19
- Days to decision
- 89 days
- Decision code
- APPR
- Product code
- PJG
- Advisory committee
- Pathology
- Expedited review
- No
- Location
- Salt Lake Cit, UT
- Statement
- Approval for the BRACAnalysis CDx®, for gBRCA mutated ovarian cancer patients maintenance monotherapy with Lynparza® (olaparib).
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.